S-1: Tenon Medical Files for Resale of Up to 5,014,654 Shares of Common Stock by Lincoln Park Capital

Tenon Medical has filed a registration statement for the resale of up to 5,014,654 shares of its common stock by Lincoln Park Capital Fund, LLC.

Summary

• Tenon Medical has filed a Form S-1 registration statement with the SEC to register the resale of up to 5,014,654 shares of its common stock by Lincoln Park Capital Fund, LLC.
• These shares include 14,654 outstanding shares already held by Lincoln Park and up to 5,000,000 additional shares that may be issued to Lincoln Park under a Purchase Agreement.
• Tenon Medical will not receive any proceeds from the sale of shares by Lincoln Park.
• The company may receive up to approximately $9.9 million in gross proceeds from any sale of common stock to Lincoln Park under the Purchase Agreement.
• The company is an emerging growth company and a smaller reporting company, which allows it to comply with certain reduced public company disclosure requirements.
• Tenon Medical's common stock is listed on The Nasdaq Capital Market under the symbol TNON, and on May 9, 2024, the closing sale price was $0.8432.
• The company has been notified by Nasdaq that it is not in compliance with the minimum bid price requirement and has until November 4, 2024, to regain compliance.
• The company is evaluating its options for regaining compliance with Nasdaq listing rules.
• The company has a limited operating history and may face difficulties encountered by early-stage companies in new and rapidly evolving markets.
• The company is dependent on a limited number of contract manufacturers, some of them single-source and some of them in single locations, for its product, and the loss of any of these contract manufacturers, or their inability to provide us with an adequate supply of products in a timely and cost-effective manner, could materially adversely affect our business.

Sentiment

Score: 4

Explanation: The document is primarily factual, but the notification of non-compliance with Nasdaq listing requirements and the potential for dilution create a negative sentiment.

Positives

• The company may receive up to approximately $9.9 million in gross proceeds from any sale of common stock to Lincoln Park under the Purchase Agreement.
• The company is an emerging growth company and a smaller reporting company, which allows it to comply with certain reduced public company disclosure requirements.

Negatives

• Tenon Medical's common stock is listed on The Nasdaq Capital Market under the symbol TNON, and on May 9, 2024, the closing sale price was $0.8432.
• The company has been notified by Nasdaq that it is not in compliance with the minimum bid price requirement and has until November 4, 2024, to regain compliance.
• The company has a limited operating history and may face difficulties encountered by early-stage companies in new and rapidly evolving markets.
• The company is dependent on a limited number of contract manufacturers, some of them single-source and some of them in single locations, for its product, and the loss of any of these contract manufacturers, or their inability to provide us with an adequate supply of products in a timely and cost-effective manner, could materially adversely affect our business.

Risks

• The sale or issuance of our common stock to Lincoln Park may cause dilution and the sale of the shares of common stock acquired by Lincoln Park, or the perception that such sales may occur, could cause the price of our common stock to fall.
• We may not be able to satisfy listing requirements of Nasdaq to maintain a listing of our common stock.
• Future sales and issuances of our securities could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall.
• If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.
• The price of our common stock may be volatile, and you may be unable to resell your shares at or above the price paid.
• Our failure to maintain effective internal controls over financial reporting could have an adverse impact on us.
• We may be subject to securities litigation, which is expensive and could divert our managements attention.
• We are an emerging growth company under the JOBS Act of 2012 and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors.
• We have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of our stock.
• The elimination of personal liability against our directors and officers under Delaware law and the existence of indemnification rights held by our directors, officers and employees may result in substantial expenses.
• Our Certificate of Incorporation will designate the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders ability to obtain a favorable judicial forum for disputes with us.

Future Outlook

The company expects to use any net proceeds from the sale of its common stock to Lincoln Park for general corporate purposes, including working capital.

Industry Context

This announcement is typical for companies utilizing equity lines of credit to raise capital. It reflects the company's ongoing efforts to secure funding for its operations and growth.

Comparison to Industry Standards

• The use of equity lines of credit is a common practice among small-cap and micro-cap companies seeking flexible access to capital.
• Comparable companies like SI-Bone, Globus Medical, Medtronic plc, XTant Medical Holdings, Inc., and RTI Surgical, Inc. may utilize different financing strategies based on their size, stage of development, and access to capital markets.
• The specific terms of the Purchase Agreement with Lincoln Park, such as the commission structure and the Beneficial Ownership Cap, are generally consistent with industry standards for similar financing arrangements.

Related Party Transactions

• The Purchase Agreement with Lincoln Park Capital Fund, LLC is a related party transaction.

Stakeholder Impact

• Shareholders may experience dilution if the company sells additional shares to Lincoln Park.
• The company's ability to execute its business plan may be affected if it cannot access the capital available under the Purchase Agreement.

Next Steps

• Tenon Medical is currently evaluating its options for regaining compliance with Nasdaq listing rules.
• The company may sell shares of common stock to Lincoln Park under the Purchase Agreement.

Key Dates

Keywords

common stock, Lincoln Park Capital, resale, registration statement, securities, Tenon Medical, TNON, shares